Related Experiment Video
Updated: Mar 6, 2026

Location, Dissection, and Analysis of the Murine Stellate Ganglion
Published on: December 22, 2020
Cardiac sympathetic denervation 100years later: Jonnesco would have never believed it
Peter J Schwartz1, Gaetano M De Ferrari2, Luigi Pugliese3
1Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Abstract:
One hundred years have elapsed since Thomas Jonnesco performed the first left cardiac sympathetic denervation (LCSD) in a patient with unmanageable angina pectoris and ventricular tachyarrhythmias, and the progress in the field has surpassed imagination. Here we will review the historic basis of cardiac sympathectomy for the management of life-threatening arrhythmias and will then discuss the often forgotten critical experimental studies that provided the rationale for the amazing growth of its role in clinical management. We will then mention the evolution in the surgical approaches, with their pros and cons. Similarly, we will address the existence of different views on the wisdom of starting with unilateral LCSD versus performing at outset bilateral CSD. The main results in the two diseases for which LCSD has already a definite role (namely the long QT syndrome and catecholaminergic polymorphic ventricular tachycardia) will be reviewed and discussed, touching also on the medico-legal implications descending from the clear efficacy of LCSD for these conditions. Finally, we will consider the potential value of LCSD for other clinical conditions and will close by mentioning a new randomized clinical trial in which LCSD is performed in patients with heart failure.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Cardiomyopathy II: Dilated Cardiomyopathy
Drugs Acting on Autonomic Ganglia: Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

